Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321452 | 0.84 | MAOB (0.48) | MAOBMEN1KMT2ALMNAIDO1 | |
| SCHEMBL18707380 | 0.83 | FFAR4 (0.48) | MAOBALDH1A1IDO1MRGPRX4L3MBTL1 | |
| SCHEMBL18707424 | 0.82 | APP (0.47) | MAOBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL339374 | 0.82 | HTR1A (0.53) | MAOBMEN1KMT2ASMN1; SMN2MRGPRX4 | |
| SCHEMBL5475735 | 0.82 | MAOB (0.51) | MAOBMEN1KMT2ALMNAIDO1 | |
| SCHEMBL985802 | 0.82 | EGFR (0.47) | MAOBLMNAIDO1AGXTMRGPRX4 | |
| SCHEMBL12864874 | 0.77 | MAOB (0.56) | MAOBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL182637 | 0.76 | HTR1A (0.53) | MAOBKMT2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL17210836 | 0.76 | MAOB (0.55) | MAOBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL1406548 | 0.76 | MAOB (0.60) | MAOBMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020391-B2 | CRMP2 sumoylation inhibitors and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200093822-A1 | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-03-26 | — | — | US | disclosed |
| US-10441586-B2 | CRMP2 SUMOylation inhibitors and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180289700-A1 | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF | Arizona Board of Regents on Behalf of the University of Arzona (US) | 2018-10-11 | — | — | US | disclosed |
| WO-2017062804-A1 | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-04-13 | — | — | WO | disclosed |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-6727256-B1 | 4-AMINOQUINAZOLINE DERIVATIVES AS ANTICARCINOGENIC AGENTS | SMITHKLINE BEECHAM CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6713485-B2 | ANTIPROLIFERATIVE AGENTS; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| EP-1294715-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| WO-2002002552-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093822-A1 | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF | SUMO2, SUMO1, SUMO3 | MAOB 4335/4885MEN1 2976/4885KMT2A 1640/4885 |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | CCNH, HRH2, HRH1 | MAOB 110/4885MEN1 215/4885KMT2A 385/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | MAOB 945/4885MEN1 3421/4885KMT2A 2440/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885MEN1 2579/4885KMT2A 1174/4885 |
| US-11020391-B2 | CRMP2 sumoylation inhibitors and uses thereof | SUMO2, SUMO1, SUMO3 | MAOB 4335/4885MEN1 2976/4885KMT2A 1640/4885 |
| US-20180289700-A1 | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | MAOB 4500/4885MEN1 2377/4885KMT2A 2198/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885MEN1 2579/4885KMT2A 1174/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885MEN1 2579/4885KMT2A 1174/4885 |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | ERBB4, ABL1, ERBB2 | MAOB 3698/4885MEN1 1322/4885KMT2A 1454/4885 |
| US-10441586-B2 | CRMP2 SUMOylation inhibitors and uses thereof | SUMO1, SUMO2, SUMO3 | MAOB 4500/4885MEN1 2377/4885KMT2A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.